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Abstract
Background: The present study describes Complementary and Alternative Medicine (CAM) use amongst Italian
women transitioning through menopause. Popularity and perceived effectiveness of CAM treatments, use of
pharmaceutical medications, characteristics of CAM users, the extent of communication between medical
practitioners and women about their use of CAM, and variables associated with CAM use were also investigated.
Methods: Women, aged 45-65 years attending Family Planning and Women’s Health clinics or Menopause Centres
in Bologna were invited to complete a voluntary, anonymous, self administered questionnaire, which was used in a
previous study in Sydney. The questionnaire was translated and adapted for use amongst Italian women. Data on
general demographic and health characteristics, menopause related symptoms and the use of CAM and
pharmaceutical treatments during the previous 12 months were collected.
Results: In total, 1,203 women completed the survey, of which 1,106 were included in the final sample. Of women
who had symptoms linked with menopause and/or used remedies to alleviate symptoms, 33.5% reported to have used
CAM. Among these, 23.5% had consulted one or more practitioners and 24% had used at least one CAM product.
Approximately nine out of ten respondents reported medical practitioners did not seek information about their use
of CAM; while one third of CAM users did not disclose the use of CAM to their physician. Nevertheless, medical
practitioners were the most popular source of information. From the multivariate analysis, variables associated with
CAM use were: professional employment, time since the last natural menses, use of CAM for conditions other than
menopause, and presence of some severe symptoms.
Conclusions: The relatively high prevalence of CAM use by women transitioning through menopause should
encourage research initiatives into determining which CAM treatments are the safest and effective. The increasing
and likely concomitant use of CAM with HRT and other pharmaceuticals underlines the need for the
implementation of a surveillance system to report and monitor possible drug-herb adverse events. The discrepancy
between women preferring to seek information about CAM from their medical doctor and the difficulties noted in
communication between doctor and patient should encourage educational initiatives on CAM by health-care
agencies and institutions.
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A significant proportion of women experience symptoms
during the peri-menopause and Hormone Replacement
Therapy (HRT) is often prescribed to alleviate these symp-
toms [1]. However, despite the effectiveness of HRT [2],
many women refuse or discontinue treatment because of
side effects such as vaginal bleeding, bloating and breast
tenderness or due to concerns about an increased risk of
cancer or other HRT-linked conditions [3-8]. Therefore,
many women are seeking safer alternative therapies to
relieve symptoms and improve quality of life [9-19]. A large
number of these treatments come under the broad term of
Complementary and Alternative Medicine (CAM). This
term refers to a wide range of diagnostic and therapeutic
practices whose theoretical bases are different from those
of the dominant scientific medical model. While in Italy the
term generally used is “Non-conventional Medicine”,t h i s
article uses the term CAM in order to be consistent with
terminology used by colleagues and collaborators at Com-
pleMED for present and future work. The terms “CAM
products” and “CAM treatments” refer to preparations and
treatments prescribed within their respective CAM domain,
while the term “CAM practitioners” includes care-givers
who may or may not be medical doctors.
In Italy, as in other developed countries, the range of
CAM treatments for improving quality of life during the
menopausal transition is diverse. Modalities include self-
care techniques, treatments that require consultations
with qualified professionals and/or the use of herbal or
homeopathic products.
Although a number of studies have investigated the
use of CAM during the menopausal transition [9-19],
only one study was conducted in Italy [20], which inves-
tigated the use of HRT and other treatments for meno-
pausal syndrome amongst a convenience sample of
female medical doctors and the wives of doctors.
However, the findings from such a sample do not give
a clear representation of the use of CAM. Therefore, the
present study, although based on a convenience sample
as well, aimed to obtain a more clear insight on the nat-
u r eo fC A Mu s ea m o n g s tal a r g e rs a m p l eo fI t a l i a n
women transitioning through menopause who were
symptomatic or asymptomatic but taking treatments for
menopausal related symptoms. We also investigated the
popularity and perceived effectiveness of CAM treat-
ments, the use of pharmaceutical medications, the char-
acteristics of CAM users and the extent of
communication between medical practitioners and
women about their use of CAM.
Methods
This project was approved by the Ethics Committee of
the Local Health Unit of Bologna and was conducted in
collaboration with CompleMED, the Centre for Comple-
mentary Medicine, University of Western Sydney. The
questionnaire, originally developed, validated and used
in a similar study [19], was translated into Italian (see
Additional file 1). The original list of CAM products
and CAM practitioners was modified to include modal-
ities most likely to be used by Italian women. The 19
item questionnaire collected data on general demo-
graphic and health characteristics, menopause related
symptoms and the use of CAM and pharmaceutical
treatments during the previous 12 months. “Natural
menses” was defined as a menstrual period not brought
on by HRT or other medications. The menstrual status
was determined from the date of the last natural menses
as either having occurred more than 12 months ago,
between 2 and 11 months or last month. The severity of
symptoms related to menopause was rated according to
a scale from 0 (no discomfort) to 6 (extreme discom-
fort). For clarity in interpreting the results, the severity
scores were collapsed to produce three categories (0-1:
none; 2-4: mild; 5-6: severe). We defined “CAM users”
as women who had consulted at least one CAM practi-
tioner (herbalist, nutritionist, naturopath, acupuncturist,
traditional Chinese medical (TCM) doctor, homeopath
or other practitioner) and/or used at least one CAM
product (soy food or tablets, Cimicifuga racemosa pre-
parations, Angelica sinensis preparations, phytoestrogens
extracted from Dioscorea villosa or Trifolium pratense,
traditional Chinese herbal formulae, homeopathic pills
or other product). Women rated the effectiveness of
each CAM treatment they used on a scale from 0 (no
effect) to 6 (very effective). As with symptom severity,
the perceived effectiveness scores for both practitioners
and products were collapsed to produce three categories
(0-1: not effective; 2-4: moderately effective; 5-6: very
effective). Women were also asked where they had
obtained information and advice regarding CAM and
whether they had informed their doctor about their use
of CAM.
Based on the results from previous studies [9,10], we
calculated a sample size of approximately 1,200 women,
which would allow an estimate of CAM use prevalence
up to a 25% with a fixed precision of 2.5%.
This sample size was considered large enough to be
able to make later comparisons with the sample recruited
in Sydney [19]. Women, aged 45-65 years who were lit-
erate in Italian and who attended one of seven Family
Planning and Women’s Health (FP & WH) clinics of the
Bologna Local Health Unit or two Menopause Centres
(one located at a hospital and the other at a territorial
center) were invited to complete the voluntary, anon-
ymous and self administered questionnaire. Over two
years the questionnaire was distributed to eligible women
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and centers after information about the purpose of the
study was given and informed consent was obtained.
Women completed the questionnaire in the waiting
room before or immediately after a consultation. Com-
pleted questionnaires were placed in a specifically desig-
nated closed container stationed in the same room.
Women were excluded from the study if they had com-
pleted less than 80% of the questionnaire, were not
within the designated age range, were asymptomatic but
not taking specific treatments for menopausal symptoms
or if the use or non-use of CAM was unclear.
Data was entered using the software package EpiInfo
2000. All statistical analyses were conducted by the
CNESPS (National Centre of Epidemiology, Health Sur-
veillance and Promotion, Italian National Health Insti-
tute, Rome) using the program STATA 8.0 (Stata
Corporation, College Station, TX, USA). Data were
expressed as percentages, except age which was
expressed as the mean and standard deviation (SD). Dif-
ferences between groups were assessed using the c
2 test
for categorical variables and either the Mann-Whitney
test (two groups) or the Kruskal-Wallis test (three or
more groups) for ordinal variables. In order to deter-
mine the characteristics associated to CAM use, we cal-
culated prevalence ratios (PRs) with a multivariate
Poisson regression using a robust error variance. All
variables in the model were entered on the basis of a
previous exploratory univariate analysis. Statistical sig-
nificance was set at 5% (p < 0.05).
Results
Demographic and general health characteristics
General demographic and health characteristics for the
total sample and by therapy used are presented on
Table 1. In total, 1,203 women completed the survey, of
which 1,106 were included in the final sample. Women
were excluded if they were older or younger than the
specified age range (n = 45), asymptomatic and not
using a therapy specific for menopausal complaints (n =
32) or if the use or non-use of CAM was unclear (n =
27). The majority of respondents completed the ques-
tionnaire at a FP&WH clinic, while 14% were completed
at Menopause Centers. No significant differences were
observed between recruitment groups in regards to age,
marital status, education, employment, menstrual status,
prevalence of CAM use and communication with doc-
t o r s .H o w e v e r ,s i g n i f i c a n t ly more women attending a
FP&WH clinic used CAM for other conditions unre-
lated to menopause. HRT was used more frequently by
women from Menopause Centres. Respondents attend-
ing FP&WH clinics regarded their general health to be
better and their symptoms to be less severe than
recruits from Menopause Centres, although these
differences were not relevant and not statistically signifi-
cant. Since there were few significant differences
between recruitment groups and because of an imbal-
ance in numbers between these groups, we decided to
conduct the analyses according to the type of therapy
used to alleviate menopausal symptoms in the overall
cohort.
Use of CAM and HRT for menopausal symptoms
The majority of women (56.2%) reported they had not
used any treatment for menopausal complaints during
the previous 12 months. Of women who had used
remedies to alleviate symptoms, 10.3% had used HRT
alone, 26.7% had used CAM exclusively, while 6.8% had
used CAM in conjunction with HRT. Overall, 33.5%
had used CAM during the twelve months before ques-
tionnaire completion. Among CAM users, one in five
(20.5%) women had reported using CAM together with
HRT, while 15.7% of CAM non users had used HRT
(p < 0.05).
In terms of CAM practitioner use, 23.5% of women
had consulted one or more practitioners; 15.5% had vis-
ited one practitioner and 8% had seen two or more.
Approximately 24% of women had used at least one
CAM product during the previous 12 months. Of these
women, 15.8% had used one product while 7.8% had
used two or more. More than half (55.5%) of the
women who consulted a practitioner had also used one
or more CAM products. The three most popular practi-
tioners consulted were the herbalist, nutritionist and
homeopath (Figure 1). The most popular practitioners
recorded in the “other” category were the osteopath and
yoga teacher. The most popular products were herbal
products (which included Cimicifuga and phytoestro-
gens extracted from Dioscorea, soy or other plants in
the form of pills or decoctions) (41.4%) and additional
soy in the diet (26.2%) (Figure 2). Please note; women
who took several products within a category were
counted once for that category.
Health status and perceived effectiveness of
CAM modalities
The majority of women who used any therapy to allevi-
ate menopausal symptoms reported their general health
to be good. The current health status reported by
women using CAM treatments did not differ when com-
pared to women taking HRT (p = 0.14). The current
perceived health of respondents not using any treatment
for menopause was significantly better when compared
to women who used CAM (p < 0.01). CAM users
reported a number of symptoms to be more severe
compared to non-users including: sleep disturbance,
tension, mood, hot flushes, muscle pain, accelerated
heartbeat and sweating.
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as perceived by respondents are presented on Figures 3
and 4. The most effective products were TCM herbal
formulae, Cimicifuga preparations and phytoestrogens.
The most effective practitioners were the TCM doctor,
homeopath, acupuncturist and naturopath.
Communication about CAM with medical practitioners
Approximately nine out of ten respondents reported
medical practitioners did not seek information about
their use of CAM; CAM users were more often ques-
tioned by doctors than non users (19.9% and 7.9%
respectively, p <0.001). Thirty one percent of CAM
Table 1 Demographic and health characteristics for the total sample and by therapy used
Variables Total sample
N = 1106
CAM
N = 295
HRT
N = 114
CAM & HRT
N=7 5
P*
Age (at 2006), mean ± SD 56.0 ± 5.3 55.8 ± 4.9 56.3 ± 5.2 55.6 ± 4.1 0.56
Marital status, n (%)
Without partner 249 (22.7) 77 (26.4) 21 (18.4) 21 (24.7) 0.19
With partner 849 (77.3) 215 (73.6) 93 (81.6) 54 (75.3)
Education, n (%)
Primary school 453 (41.0) 106 (36.2) 30 (26.3) 25 (33.3)
High school 473 (42.9) 131 (44.7) 57 (50.0) 33 (44.0) 0.41
University 178 (16.1) 56 (19.1) 27 (23.7) 17 (22.7)
Occupation, n (%)
Unemployed 454 (41.8) 113 (39.0) 49 (44.1) 22 (30.1)
Non professional 157 (14.5) 40 (13.8) 6 (5.4) 7 (9.6) 0.05
Professional 475 (43.7) 137 (47.2) 56 (50.5) 44 (60.3)
Birth place, n (%)
Bologna city 586 (53.5) 150 (51.4) 71 (62.3) 43 (57.3)
Bologna province 183 (16.7) 56 (19.2) 17 (14.9) 12 (16.0) 0.38
Other 327 (29.8) 86 (29.4) 26 (22.8) 20 (26.7)
Recruitment, n (%)
FP&WH Clinic ** 950 (85.9) 269 (91.2) 84 (73.7) 56 (74.7)
Menopause Center 156 (14.1) 26 (8.8) 30 (26.3) 19 (25.3) < 0.001
Last menstruation, n (%)
≥ 12 months 670 (64.2) 188 (66.2) 87 (79.8) 56 (77.8)
2-11 months 140 (13.4) 41 (14.5) 10 (9.2) 12 (16.7) 0.012
Last month 192 (18.4) 43 (15.1) 8 (7.3) 1 (1.4)
Surgical menopause 42 (4.0) 12 (4.2) 4 (3.7) 3 (4.2)
CAM for other conditions, n (%)
No 856 (84.2) 175 (64.1) 101 (95.3) 47 (72.3) < 0.001
Yes 161 (15.8) 98 (35.9) 5 (4.7) 18 (27.7)
Use of other drugs, n (%)
No 567 (51.3) 156 (52.8) 71 (62.3) 41 (54.7) 0.23
Yes 539 (48.7) 139 (47.2) 43 (37.7) 34 (45.3)
Current health, n (%)
Poor (1-3) 104 (9.5) 37 (12.6) 8 (7.0) 4 (5.4)
Good (4-5) 587 (53.5) 161 (55.0) 65 (57.0) 39 (52.7) 0.18
Excellent (6-7) 406 (37.0) 95 (32.4) 41 (36.0) 31 (41.9)
Past health, n (%)
Worse (1-3) 188 (17.3) 55 (18.8) 22 (19.6) 12 (16.0)
Same (4-5) 574 (52.7) 162 (55.5) 59 (52.7) 38 (50.7) 0.74
Better (6-7) 328 (30.1) 75 (25.7) 31 (27.7) 25 (33.3)
Menopausal symptoms, n (%≥5):
Severe hot flushes 187 (18.6) 74 (26.6) 12 (12.0) 25 (34.7) 0.01
Severe insomnia 214 (21.3) 78 (29.7) 19 (18.5) 17 (24.3) 0.08
Severe mood 132 (13.4 43 (16.0) 13 (12.4) 13 (19.1) 0.48
* significant statistical level for difference between CAM, HRT, CAM and HRT use groups
** FP&WH Clinic = Family Planning and Womens’ Health Clinic
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Figure 2 Products used by CAM users (n = 370). NB: Herbal products includes Cimicifuga and phytoestrogens from Dioscorea, Soy or other
plants, in pills or decoctions.
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Figure 4 Proportion of CAM users who found practitioners to be highly, mildly or not effective (%). NB: Other herbal products include
mixed preparations of phytoestrogens and Cimicifuga.
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cian. It is worth noting, that 83 women (22%) who
declared they had never used CAM, were in fact users
as they had consulted at least one practitioner and/or
used at least one product. Approximately half of the
respondents (48.7%) were using prescription medications
other than CAM and HRT. This proportion was similar
for both CAM and non-CAM users (46.8 and 49.7%
respectively).
Sources of information about CAM
Women accessed a wide range of sources to obtain
information about CAM. The most popular sources of
information were medical practitioners (25%), books and
herbalists (15% each), magazines (14%), friends or neigh-
bours (13%) and pharmacists (12%). The most fre-
quently consulted practitioner in the “other” category
(completed by 8% of respondents) was the gynaecologist.
Television (3%) and the Internet (2%) were the least fre-
quently used sources of information.
Variables associated to CAM use: multivariate analysis
Variables analyzed in a multivariate model in order to
detect the characteristics associated to CAM use were:
age, occupation, health status, birth place, the use of
CAM for other conditions, education, date of last
menses, marital status and severity of menopausal symp-
toms. HRT users (n = 114) and women with surgical
menopause (n = 42) were excluded from the analyses.
From the multivariate Poisson model, the variables asso-
ciated with CAM use were determined to be: employ-
ment, with an increased prevalence of CAM use by 48%
for women in professional employment compared to
those without employment; time since the last natural
menses, with the highest CAM prevalence amongst
women whose last menses occurred between 2 and 11
months prior to the survey; use of CAM for conditions
other than menopause, with a prevalence greater than
twice amongst women who had used CAM for other
conditions; and the presence of severe symptoms,p a r -
ticularly night sweats and sleep disorders. Statistically
significant PRs(95% CI) are presented in Table 2.
Discussion
One third of our sample, including women aged 45-65
years and attending FP & WH Clinics or Menopause Cen-
ters in Bologna, reported to have used at least one CAM
modality for menopausal complaints during the 12 months
prior to the survey. Previously conducted studies investi-
gating the use of CAM amongst menopausal women
reported a wide range in prevalence rates [9-12]. These dif-
ferences may be due to varying research methodologies
and/or the number of modalities included as CAM. Never-
theless, when compared to the outcomes of studies incor-
porating similar methodologies and large sample sizes, our
results indicate that CAM is utilized less frequently in
Bologna [9-12,19]. According to the 2005 Multiscope Sur-
vey conducted by the Italian National Institute of Statistics
(ISTAT), 20.4% of Italian women aged 45-55 years, and
17% of women aged 55-64 years used at least one CAM
treatment during the previous three years [21]. The higher
prevalence of use reported by our respondents may be due
to different inclusion criteria, as we selected for women
with menopausal symptoms. Furthermore, sociological fac-
t o r sm a ya l s op l a yar o l ei nt h eu p t a k eo fC A Mu s ei n
Bologna. The national Multiscope Survey [21] determined
that consumers of CAM tended to be middle-aged, better
educated and have higher disposable incomes than non-
users. CAM use was also found to be more prevalent in
richer north-eastern regions of Italy [21,22]. Our survey
was conducted in an affluent area with adequate medical
health care services and facilities, therefore the use of
CAM for menopausal complaints in Bologna may be sig-
nificantly higher than other areas of Italy.
We found that respondents in Bologna were more
likely to take CAM products than to see a practitioner,
but this difference is less than in other surveys con-
ducted abroad [9,19]. This could be due to the fact that
in Italy CAM products are sold only in pharmacies or
herbalist’s shops, while in other countries these products
are also sold in supermarkets.
Respondents preferred taking soy as food and/or phy-
toestrogens rather than other CAM products. The addi-
tion of soy containing foods to the diet is an easy and
inexpensive way to increase phytoestrogen consumption
[9,19]. Therefore, our observation supports the hypoth-
esis that CAM users orient their choices towards simple
and less expensive products. Respondents regarded
Table 2 Prevalence Ratios and 95% CI for significant
associations with CAM use
PR P (95% CI)
Occupation (vs none):
Non professional 1.03 0.85 (0.74-1.45)
Professional 1.48 0.00 (1.17-1.87)
CAM for other reasons (yes vs no) 2.19 0.00 (1.85-2.60)
Last natural menses (vs last month)
2-11 months 1.73 0.00 (1.27-2.36)
≥ 12 months 1.58 0.01 (1.12-2.25)
Symptoms and discomfort (vs none)
Night sweats Mild 0.93 0.61 (0.69-1.24)
Severe 1.51 0.01 (1.09-2.09)
Insomnia Mild 1.45 0.00 (1.14-1.86)
Severe 1.63 0.00 (1.23-2.16)
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Cimicifuga to be the most effective products. Despite
individual clinical trial outcomes suggesting that phy-
toestrogens isolated from soy and other herbs may con-
fer a moderate effect in alleviating menopausal
symptoms, the effectiveness of isoflavones and phytoes-
trogens were not assessed and therefore remains contro-
versial [23,24]. Contrary to the findings of the
Multiscope Italian survey (which refers to the general
population), our respondents consulted with herbalists
and nutritionists, more often than homeopaths and
manipulative therapists such as osteopaths, chiropractors
and massage therapists [21,22]. The findings that manip-
ulative treatments were not commonly utilised for
menopausal complaints by respondents contrasts those
of the original survey conducted in Sydney [19].
Our results indicate that, amongst both CAM users
and non users, almost one in two respondents used
pharmaceutical medications within the past year.
Approximately 20% of CAM users had taken HRT dur-
ing the previous 12 months. However, we were unable
to ascertain if pharmaceuticals were used concurrently
or sequentially with CAM treatments. Nevertheless,
these significantly high usage rates indicate a need to
improve our knowledge of and to strengthen our sur-
veillance measures for detecting possible interactions
between CAM and pharmaceutical medications [25,26].
Our results confirm a lack of communication between
physicians and patients on the use of CAM [27], which
makes monitoring the use of medications difficult. This
lack of communication was bi-directional, as 9 out of 10
respondents indicated that GPs did not discuss their use
of CAM, while two out of five CAM users disclosed
their use of alternative therapies to their doctor. It was
interesting to note the high number of missing (8%) and
inconsistent answers (22%) to the question “do you
usually tell your medical doctor when using CAM?”.
The fact that one in five CAM users answered “Ih a v e
never used CAM” indicates a gap in communication
which may be due to either a confusion over the defini-
tion of “complementary medicine” or the purposeful
concealment of the use of CAM, possibly due to the
belief that declaring the use of CAM may negatively
interfere with the healing relationship between doctor
and patient. This worry is rather common and has been
described in previous studies. A national survey con-
ducted in the U.S. [28] found more than one third of
r e s p o n d e n t sd e c l a r e dt h e yd i dn o td i s c l o s et h eu s eo f
CAM to their doctors because “the doctor would not
understand” (20%), “would disapprove of or discourage
CAM use” (14%) or “might not continue as their provi-
der” (2%). Despite these concerns, participants in our
study indicated the medical doctor as the most fre-
quently consulted source of information about CAM.
The Internet was one of the least consulted sources,
possibly due to the age of respondents, who are more
likely to be computer illiterate. Use of the Internet as a
source of information may increase in popularity as suc-
cessive more computer-literate generations reach meno-
pausal age. Since Italian television has dedicated little
time to the exploration of CAM, television as a source
of information was rated poorly.
The most significant variables associated with CAM
use were: having used CAM for other conditions, the
presence of severe symptoms, being post menopausal
and professionally employed. If a woman had used
CAM for other conditions, she was around two times
more likely to use CAM for menopausal complaints:
this may indicate a level of satisfaction with previous
CAM use, warranting its use for menopausal symptoms.
Postmenopausal women with severe symptoms were
more likely to be users of CAM. The disruption of sleep
due to night sweats (more than any other symptom,
including hot flushes) may instigate the use of alterna-
tive treatments, as women may no longer tolerate symp-
toms that affect daytime mood and performance.
Finally, women who have higher disposable incomes
were more likely to use CAM, which is consistent with
the findings of previous surveys [21].
Strengths and limitations
T oo u rk n o w l e d g e ,t h i si st h ef i r s tc o m p r e h e n s i v es u r -
vey conducted in Italy that explores the use of CAM
by symptomatic women or by women who were
asymptomatic but taking menopause specific treat-
ments during the menopausal transition. The Italian
translation of the questionnaire was validated for face
and content by a panel of experts who reviewed and
adapted it to the Italian context; it was not validated
for repeatability and reliability, given that this had
already been done in Australia for the original ques-
tionnaire (19). We acknowledge that some limitations
of our study make the extrapolation of our results to
the general population difficult. The use of conveni-
ence sampling of women from a number of health
clinics may have over inflated the use of CAM and the
reporting of menopausal symptoms. Furthermore, the
voluntary self administration of the questionnaire may
have selected for respondents who were more inter-
ested in CAM thereby overestimating the true preva-
lence of CAM use. Despite these limitations, we
believe our study is valuable in highlighting the popu-
larity of CAM use by symptomatic menopausal
women. Strengths of the survey included the large
sample size of women recruited throughout the
B o l o g n ar e g i o n ,a n dt h a tw ee x p l o r e dt h eu s ea n dp e r -
ceived effectiveness of both CAM practitioners and
products.
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The results of this survey highlight a number of issues
relating to the use of CAM during the menopausal tran-
sition for women in Bologna. The increasing and likely
concomitant use of CAM with HRT and other pharma-
ceuticals may necessitate a need for the implementation
of a surveillance system to report and monitor possible
drug-herb adverse events.
The discrepancy between women preferring to seek
information about CAM from their medical doctor and
the difficulties noted in communication between doctor
and patient should encourage educational initiatives on
CAM by health-care agencies and institutions. Patients
should be informed about the risks and benefits of
CAM, while health care professionals (particularly pri-
mary care practitioners) should be encouraged to com-
municate effectively with patients about their use of
CAM and pharmaceuticals, and clearly record all medi-
cations consumed, signaling any possible adverse events
or interactions.
T h eh i g hp r e v a l e n c eo fC A Mu s eb yw o m e nt r a n s i -
tioning through menopause should encourage research
initiatives into determining which CAM treatments are
the safest and effective, giving priority to treatments
identified by the literature as the most promising and
the most popular; however keeping in mind that popular
treatments may not always equate to the most effective.
Additional file 1: CAM - Menopause questionnaire (Italian).pdf.
questionnaire administered in the study.
Click here for file
[http://www.biomedcentral.com/content/supplementary/1472-6874-10-7-
S1.PDF]
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